Clinical Trials Browser

Phase 1 × CB-839 × Plasma cell × Clear all

NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Phase 1 Completed

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma